Figure 7
Figure 7. Engraftment of human bone marrow cells in NOD-Scid IL2Rγnull mice. (A-C) Primary transplantation. Human bone marrow CD34+ cells were cultured in the presence of myeloid cytokines with or without TAT-NF-Ya for 3, 6, or 9 days and then transplanted into sublethally irradiated NOD-Scid IL2Rγnull mice. (D) Secondary transplantation. Bone marrow recovered from primary recipient mice was transplanted in secondary recipients to evaluate the capacity of Scid repopulating cells. Nine weeks after primary or secondary transplantation, mice were killed and bone marrow cells were analyzed for the presence of human CD45+ (A,D), myeloid CD33+ (B), and lymphoid CD19+ (C) cells by flow cytometry. Results are pooled from 3 transplantation experiments. Increased recovery of huCD45+ cells was seen in the TAT-NF-Ya–treated groups in each experiment. The proportion of lymphoid and myeloid engrafted populations was not significantly different in control and protein-treated cells. *P < .05.

Engraftment of human bone marrow cells in NOD-Scid IL2Rγnull mice. (A-C) Primary transplantation. Human bone marrow CD34+ cells were cultured in the presence of myeloid cytokines with or without TAT-NF-Ya for 3, 6, or 9 days and then transplanted into sublethally irradiated NOD-Scid IL2Rγnull mice. (D) Secondary transplantation. Bone marrow recovered from primary recipient mice was transplanted in secondary recipients to evaluate the capacity of Scid repopulating cells. Nine weeks after primary or secondary transplantation, mice were killed and bone marrow cells were analyzed for the presence of human CD45+ (A,D), myeloid CD33+ (B), and lymphoid CD19+ (C) cells by flow cytometry. Results are pooled from 3 transplantation experiments. Increased recovery of huCD45+ cells was seen in the TAT-NF-Ya–treated groups in each experiment. The proportion of lymphoid and myeloid engrafted populations was not significantly different in control and protein-treated cells. *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal